Rupatadine for the treatment of urticaria

Bibliography

• Holgate ST, Canonica GW, Simons FE, et al. Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations. Clin Exp Allergy 2003;33(9):1305-24
   PubMed Web of Science ®Google Scholar
• Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 2011;128(6):1139-50
   PubMed Web of Science ®Google Scholar
• Izquierdo I, Merlos M, García-Rafanell J. Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. A review of pharmacological profile and clinical management of allergic rhinitis. Drugs Today (Barc) 2003;39(6):451-68
   PubMed Web of Science ®Google Scholar
• Solans A, Carbó ML, Peña J, et al. Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: a single-dose, randomized, open-label, two-way crossover study. Clin Ther 2007;29(5):900-8
   Google Scholar
• Merlos M, Giral M, Balsa D, et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther 1997;280(1):114-21
   PubMed Web of Science ®Google Scholar
• Picado C. Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. Expert Opin Pharmacother 2006;7(14):1989-2001
   PubMed Web of Science ®Google Scholar
• Kanani A, Schellenberg R, Warrington R. Urticaria and angioedema. Allergy Asthma Clin Immunol 2011;7:(Suppl 1):S9
   Google Scholar
• Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009;64(10):1417-26
   PubMed Web of Science ®Google Scholar
• Medic N, Desai A, Komarow H, et al. Examination of the role of TRPM8 in human mast cell activation and its relevance to the etiology of cold-induced urticaria. Cell Calcium 2011;50(5):473-80
   PubMed Web of Science ®Google Scholar
• Fonacier LS, Dreskin SC, Leung DY. Allergic skin diseases. J Allergy Clin Immunol 2010;125(2 Suppl 2):S138-49
   Google Scholar
• Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009;64(10):1427-43
   PubMed Web of Science ®Google Scholar
• Izquierdo I, Nieto C, Ramis J, et al. Pharmacokinetic and dose linearity of rupatadine fumarate in healthy volunteers. Meth Find Exp Clin Pharmacol 1997;19(Suppl A):189
   PubMedGoogle Scholar
• Keam SJ, Plosker GL. Rupatadine: a review of its use in the management of allergic disorders. Drugs 2007;67(3):457-74
   Web of Science ®Google Scholar
• Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy 2011;66:317-30
   PubMed Web of Science ®Google Scholar
• Weldon DR. Quality of life in patients with urticaria. Allergy Asthma Proc 2006;27(2):96-9
   Google Scholar
• Salmun LM. Antihistamines in late-phase clinical development for allergic disease. Expert Opin Investig Drugs 2002;11(2):259-73
   PubMed Web of Science ®Google Scholar
• Dubertret L, Zalupca L, Cristodoulo T, et al. Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study. Eur J Dermatol 2007;17(3):223-8
   PubMed Web of Science ®Google Scholar
• Gimenez-Arnau A, Pujol RM, Ianosi S, et al. Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicentre study. Allergy 2007;62(5):539-46
   PubMed Web of Science ®Google Scholar
• Giménez-Arnau A, Izquierdo I, Maurer M. The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo-controlled treatment with rupatadine 10 and 20 mg. J Eur Acad Dermatol Venereol 2009;23(9):1088-91
   PubMed Web of Science ®Google Scholar
• Church MK, Máspero JF, Maurer M, et al. The Scope of Pharmacological and Clinical Effects of Modern Antihistamines, With a Special Focus on Rupatadine: proceedings from a Satellite Symposium held at the 21st World Allergy Congress; 8 December 2009; Buenos Aires. World Allergy Organ J 2010;3(4 Suppl):S1-S16
   Google Scholar
• Church MK. Efficacy and tolerability of rupatadine at four times the recommended dose against histamine- and platelet-activating factor-induced flare responses and ex vivo platelet aggregation in healthy males. Br J Dermatol 2010;163(6):1330-2
   PubMed Web of Science ®Google Scholar
• Maiti R, Jaida J, Raghavendra BN, et al. Rupatadine and levocetirizine in chronic idiopathic urticaria: a comparative study of efficacy and safety. J Drugs Dermatol 2011;10(12):1444-50
   PubMed Web of Science ®Google Scholar
• Kim H, Lynde C. Impact of desloratadine on symptoms and quality of life in subjects with chronic idiopathic urticaria: a multicenter, practice-based study. Arch Drug Inf 2008;1(2):63-9
   Google Scholar
• Wanderer AA. Cold urticaria syndromes: historical background, diagnostic classification, clinical and laboratory characteristics, pathogenesis, and management. J Allergy Clin Immunol 1990;85(6):965-81
   PubMed Web of Science ®Google Scholar
• Lee CW, Sheffer AL. Primary acquired cold urticaria. Allergy Asthma Proc 2003;24:9-12
   Google Scholar
• Di Leo E, Nettis E, Cassano N, et al. Treatment of acquired cold urticaria with rupatadine. Allergy 2009;64(9):1387-8
   Google Scholar
• Metz M, Scholz E, Ferrán M, et al. Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. Ann Allergy Asthma Immunol 2010;104(1):86-92
   PubMed Web of Science ®Google Scholar
• Valero A, de la Torre F, Castillo JA, et al. Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis: a multicentre, open-label study in Spain. Drug Saf 2009;32(1):33-42
   PubMed Web of Science ®Google Scholar
• García-Gea C, Ballester MR, Martínez J, et al. Rupatadine does not potentiate the CNS depressant effects of lorazepam: randomized, double-blind, crossover, repeated dose, placebo-controlled study. Br J Clin Pharmacol 2010;69(6):663-74
   PubMed Web of Science ®Google Scholar
• Vuurman E, Theunissen E, van Oers A, et al. Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers. Hum Psychopharmacol 2007;22(5):289-97
   PubMed Web of Science ®Google Scholar
• Barbanoj MJ, García-Gea C, Morte A, et al. Central and peripheral evaluation of rupatadine, a new antihistamine/platelet-activating factor antagonist, at different doses in healthy volunteers. Neuropsychobiology 2004;50(4):311-21
   Google Scholar
• Barbanoj MJ, García-Gea C, Antonijoan R, et al. Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers. Hum Psychopharmacol 2006;21(1):13-26
   PubMed Web of Science ®Google Scholar
• Donado E, Izquierdo I, Pérez I, et al. No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a ‘thorough QT/QTc study' performed according to ICH guidelines. Br J Clin Pharmacol 2010;69(4):401-10
   PubMed Web of Science ®Google Scholar
• Caballero R, Valenzuela C, Longobardo M, et al. Effects of rupatadine, a new dual antagonist of histamine and platelet-activating factor receptors, on human cardiac kv1.5 channels. Br J Pharmacol 1999;128(5):1071-81
   Google Scholar